Abstract Information

 Abstracts are currently under review 


Please note the following important submission guidelines:
  1. The abstract deadline has been extended to February 1, 2018 at 11:59pm CST.
  2. Abstracts are limited to 250 words; figures and tables are not allowed.
  3. Abstract titles should use sentence case (i.e., only the first letter of the title should be capitalized)
  4. The body of the abstract should be in a single paragraph. If subheaders are used, they should be within that single paragraph in all-caps, not bolded (e.g., METHODS)
Abstracts of original research will be accepted in the following categories:
  • ATRT
  • Medulloblastoma – Basic/Translational
  • Medulloblastoma –  Clinical
  • Other Embryonal Tumors
  • Craniopharyngioma/Rare Tumors
  • Early Phase/Drug Discovery
  • Ependymoma
  • Epidemiology
  • Germ Cell Tumors
  • Diffuse Midline Glioma/DIPG
  • High-Grade Glioma
  • Immune Therapy
  • Low-Grade Glioma
  • Neurofibromatosis Associated Tumors (including plexiforms)
  • Neuro-Oncology in Low/Middle Income Countries
  • Neurosurgery
  • Nursing – Clinical
  • Nursing – Research
  • Preclinical Models
  • Pharmacokinetics
  • QoL/Survival/Rehab
  • Radiation Oncology
  • Radiology
  • Social Work/Patient Support
  • Tumor Biology/Pathology (not fitting a specific disease category)